Moh'd Al-Halawani, MD
Pulmonary Disease · Hutchinson, KSNPI 1003204629
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (30.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Intuitive Surgical at 49.2% of the total. Reporting peaked in 2023 at $7,542 and has fallen 77.9% since, to $1,664 in 2025.
Across 117 payments — averaging $125.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Noah Medical Corporation$3K
- Veran Medical Technologies, Inc.$917
- Bayer$600
- Sanofi$396
- Boehringer Ingelheim$309
- plus $2K from 24 others
What the payments were for
- Consulting fees$9006%
- Speaking & faculty fees$3,00020%
- Travel & lodging$4,40930%
- Food & beverage$3,22722%
- Education$3,17522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 16 | $7,232 |
| Noah Medical Corporation | 4 | $3,202 |
| Veran Medical Technologies, Inc. | 7 | $917 |
| Bayer | 3 | $600 |
| Sanofi | 14 | $396 |
| Boehringer Ingelheim | 3 | $309 |
| Jazz Pharmaceuticals Inc. | 3 | $275 |
| AstraZeneca | 9 | $273 |
| GSK | 10 | $220 |
| Regeneron Healthcare Solutions, Inc. | 8 | $175 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $166 |
| Inspire Medical Systems, Inc. | 5 | $139 |
| Pulmonx Corporation | 2 | $102 |
| Mallinckrodt Hospital Products Inc. | 2 | $98 |
| Harmony Biosciences LLC | 4 | $94 |
| United Therapeutics Corporation | 3 | $73 |
| Abiomed | 1 | $67 |
| Verona Pharma, Inc. | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 3 | $47 |
| Resmed Corp | 2 | $47 |
| Grifols USA, LLC | 3 | $43 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Genentech USA, Inc. | 2 | $28 |
| Amgen | 1 | $25 |
| Electromed, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $18 |
| AbbVie | 1 | $17 |
| Gilead | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,711 in reported general payments places this provider in the 85th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 144 | $104,428 |
| Dupixent PenDupilumab | 13 | $51,386 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $30,669 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $7,809 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,734 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $4,269 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $1,813 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,749 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,215 |
| Montelukast Sodium | 86 | $538 |
| Modafinil | 17 | $310 |
| Clonazepam | 37 | $255 |
| Eszopiclone | 14 | $108 |
| Zolpidem Tartrate | 23 | $75 |
| Azithromycin | 11 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $220 | $112,162163 claims |
| AstraZenecaBreztri Aerosphere | $273 | $30,66947 claims |
| Boehringer IngelheimStiolto Respimat | $309 | $7,80916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Hutchinson
- Robert SourkHutchinson$33K
- Humayun AshrafHutchinson$14K
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
- Brandon BowersShawnee Mission$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.